Solutions for a lifetime
Enabling ETG for the First Time

Enabling ETG
for the First Time

Xeltis develops implantable products intended to enable for the first time the spontaneous growth of natural, healthy heart valves and vessels. Read more here.

Latest News

Latest News

Xeltis closes EURO 27 million / USD 34 million series B Financing.
Read more here.

 

Xeltis AG – Zürich

Mühlebachstrasse 26
CH-8008 Zurich, Switzerland

View Map
info@xeltis.com